A potential benefit of EGFR amplified gastric cancers to anti-EGFR therapies deserves further evaluation in which, however, the frequent heterogeneity of amplification – 5/7 EGFR amplifications were heterogeneous in our patients - will have to be factored in. The gene discussed is EGFR; the disease is gastric cancer.